Pemvidutide

GLP-1 / glucagon dual agonist in trials for obesity and MASH liver disease.

Typical dose range: 1.2–2.4 mg

Frequency: Weekly

Route: Subcutaneous

Half-life: ~6 days

Evidence level: Phase 2

Overview

Altimmune's GLP-1/glucagon co-agonist with strong liver-fat reduction signals. Not yet approved.